critically ill patient News
-
CoapTech PUG System Study For Safer Procedure Performance On COVID-Positive Patients
The novel human coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), continues to infect naïve populations causing surges of critically ill patients who can survive their acute critical illness. Tracheostomy and gastrostomy are commonly paired procedures that bridge patients from their acute to subacute critical illness. Both are aerosolgenerating procedures that can ...
By CoapTech
-
Treatment for critically ill COVID patients results in significant improvement in survival rate according to new study
Patient survival doubles when Seraph 100 is used earlier during ICU stay MARTINEZ, Calif. – Critically ill patients treated with ExThera Medical’s Seraph® 100 Microbind® Affinity Blood Filter (Seraph 100) within 60 hours of ICU admission experienced a survival rate double that of patients treated after being in the ICU for 60 or more hours, according to a newly released ...
-
ExThera Medical Partners with Predicate Healthcare Performance Group to Expand Reach of Proven COVID-19 Treatment
MARTINEZ, Calif. – ExThera Medical and Predicate Healthcare Performance Group (Predicate HPG) have entered into a commercial partnership agreement in the United States for ExThera’s Seraph® 100 Microbind® Affinity Blood Filter (Seraph 100). “In Predicate HPG’s ongoing efforts to deliver evidence-based, technology-enabled care to every patient, we are pleased to ...
-
Patient Enrollment is Complete in the DOD-Funded Study of Extracorporeal Hemopurification of Critically Ill COVID-19 Patients
MARTINEZ, Calif. – PURIFY OBS, an observational study of critically-ill COVID patients treated with the Seraph® 100 Microbind® Affinity Blood Filter (Seraph 100), has recently completed enrollment. A multicenter effort led by the US Department of Defense (DOD) published interim results in April 2021. Observations included dramatic improvement in survival and reduction in median ICU ...
-
Lakhmir Chawla, MD, of Silver Creek Pharmaceuticals Joins ExThera Medical Board of Directors
Professor Lakhmir Chawla, MD, has joined the board of directors of ExThera Medical Corporation, a privately held medical technology company whose Seraph 100 Microbind Affinity Blood Filter is authorized in the United States to treat critically ill COVID-19 patients. Dr. Chawla also serves as the Chair of the Scientific Advisory Board at the company Dr. Chawla is an internationally renowned ...
-
Specific Diagnostics Announces that David Barreca, former GenMark Sales Leader, Joins Specific as
Specific Diagnostics today announced the appointment of David Barreca as Vice President of US Sales. David was a key member of GenMark’s sales leadership team, most recently a Senior Director managing a team of Account Executives that drove growth of the GenMark infectious disease diagnostics product, contributing the sales growth that led to GenMark’s acquisition by Roche Diagnostics ...
-
Liberate Medical Presents Data from its Pilot Trial of VentFree, a Muscle Stimulator for Mechanically Ventilated Patients, at the American Thoracic Society 2019 International Conference
Liberate Medical, a clinical-stage medical device company, developing novel electrical muscle stimulation devices that non-invasively address pulmonary conditions, today announced the results from its recently completed pilot trial of the VentFree Muscle Stimulator during an oral presentation at the American Thoracic Society International Conference (“ATS”) in Dallas, TX. ...
-
New Instrument for Automated Antimicrobial Susceptibility Testing Provides Gold Standard-Level Minimum Inhibitory Concentration (MIC) Accuracy[1]
A new benchtop automated reading and incubation system for antimicrobial susceptibility testing (AST) provides microbiology laboratories with the accurate MIC results that clinicians need to confidently select an effective antibiotic for critically-ill patients while safeguarding future patient care through more successful antimicrobial stewardship. Backed by a long history of AST accuracy, the ...
-
ExThera Medical & Fresenius Medical Care Sign Distribution Agreement for Seraph 100 Blood Purification Device in Mexico
Seraph 100 used for Blood Purification and Pathogen Reduction in Sepsis and COVID-19 Treatments MARTINEZ, Calif. – ExThera Medical and Fresenius Medical Care, the world’s leading provider of products and services for individuals with renal diseases, announced the expanded distribution of ExThera’s Seraph® 100 Microbind® Affinity Blood Filter in Mexico. In 2021, ExThera ...
-
Flosonics Medical selected as a winner of Vale’s COVID-19 Challenge
The company was one of two Northern Ontario organizations selected to receive financial support aimed at propelling innovative COVID-19 solutions into the marketplace Flosonics Medical was one of two Northern Ontario organizations selected as a winner of Vale’s 2020 COVID-19 Challenge. The challenge, which was launched in Canada on April 3, 2020, aimed to propel innovative COVID-19 ...
-
CARMAT announces a new commercial implant of its Aeson artificial heart at University Medical Center Schleswig-Holstein in Kiel, Germany
CARMAT (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from end-stage biventricular heart failure, today announces the third implant of its Aeson® bioprosthetic artificial heart in a commercial setting. This new commercial implant of the Aeson® device was ...
By Carmat
-
ExThera’s Affinity Blood Filter Is Used to Treat COVID-19 Patients
Treatment of COVID-19 with ExThera’s Seraph®100 Microbind® Affinity Blood Filter (Seraph 100) has begun in hospitals in Germany and Italy. Seraph 100 treatments of COVID-19 are also expected to begin soon in France and the USA. Seraph 100 is the only ‘hemoperfusion device’ approved for the reduction of pathogens in blood. In recent EU clinical cases improved lung ...
-
ExThera Medical and Asahi Kasei Medical Enter into Partnership to Expand Reach of Treatment for the Critically Ill
MARTINEZ, Calif. – ExThera Medical and Asahi Kasei Medical, a core operating company of the Asahi Kasei Group, have entered into an exclusive distribution agreement in Japan for ExThera’s Seraph® 100 Microbind® Affinity Blood Filter (Seraph 100). Per the agreement structure, ExThera Medical and Asahi Kasei Medical will collaborate to obtain regulatory approval of Seraph 100 ...
-
CARMAT announces the second center implanting its total artificial heart in the United States
The implant was performed at UofL Health – Jewish Hospital by University of Louisville physicians within the framework of the U.S. Early Feasibility Study. CARMAT (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to fulfill an unmet medical need by providing a therapeutic alternative to people suffering from end-stage ...
By Carmat
-
Fresenius Medical Care expands critical care offering with ExThera Medical’s Seraph 100 adsorber
Fresenius Medical Care, the world’s leading provider of products and services for people with chronic kidney failure, will offer the Seraph 100 Microbind Affinity Blood Filter from ExThera Medical Corporation in several European countries as of now. Both companies have signed a co-marketing and distribution agreement, effective in January 2021 and covering Belgium, Denmark, France, Germany, ...
-
Fretting Corrosion Causes Recall of Drug Delivery Medical Device
This past November, the U.S. Food and Drug Administration (FDA) announced a Class 1 recall of the Ikaria INOmax DS Drug Delivery System. The device is a drug delivery system used with ventilators to deliver a preset concentration of INOmax therapy gas (nitric oxide for inhalation) for critically ill patients. According to the FDA posting regarding the recall, “Fretting corrosion at the ...
-
Procyrion Raises $30 Million Series D to Support Clinical Trials of Its Aortix™ Percutaneous Blood Pump for Treating Heart Failure Patients
Procyrion, Inc., a clinical-stage medical device company, today announced the completion of a $30 million Series D funding round led by a new investor, Bluebird Ventures. Returning investors include Fannin Partners, Scientific Health Development, the State of Texas, and an undisclosed strategic investor. The company is developing its Aortix™ system, a percutaneous blood pump initially ...
-
VentFree Respiratory Muscle Stimulator receives FDA Emergency Use Authorization for Use During COVID-19 Pandemic
Liberate Medical today announced that it has received Federal Drug Administration (FDA) Emergency Use Authorization for its VentFree™ Respiratory Muscle Stimulator, intended to be used to reduce disuse atrophy of the abdominal wall muscles, which may reduce the number of days adult patients require mechanical ventilation, including those patients with COVID-19. Reducing the time patients ...
-
Qvella Appoints Richard Brock as VP of Global Marketing and Signals Start of Commercialization
Qvella, a diagnostics company that aims to reduce the time to results in the diagnosis of infections, today announced that it has appointed Richard Brock as VP of Global Marketing. In this role, he will lead the imminent commercialization of Qvella’s FAST-Prep™ product for Positive Blood Culture (PBC) processing. He will be responsible for the company’s go-to-market and product ...
-
Abionic launches first Covid-19 severity test to triage patients quickly and accurately
Abionic SA, a Swiss Medtech firm based in Lausanne, has developed the cSOFA score, a tool to assess the severity of Covid-19. The cSOFA score (Covid Sequential Organ Failure Assessment) measures the likelihood of clinical deterioration in Covid-19 patients, enabling triage and assignment to the general ward or intensive care units (ICU) upon admission and during the patients’ hospital stay. ...
By Abionic SA
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you